drugset / Trial / NCT05319756

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

NCT05319756

Phase 4 Completed 54 enrolled Viatris Specialty LLC
RandomizedCrossoverQuadruple-blindOther

Summary

This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational opioid users.

Timeline

Start
2021-04-30
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 600 mg Oral
Subject Gabapentin Small molecule 1200 mg Oral
Comparator Oxycodone Other / unclassified 20 mg Oral

Indications